TABLE 1.
Background characteristics and demographics of patientsa
| Characteristic | Value |
|---|---|
| Median (IQR) age (mo) (n = 93) | 28 (24–38) |
| No. (%) of male patients (n = 93) | 64 (68) |
| No. (%) of HIV-infected patients (n = 93) | 5 (5) |
| No. (%) of patients with the following country of birth (n = 93): | |
| United Kingdom | 9 (10) |
| Other western and northern Europe | 1 (1) |
| Chinese subcontinent | 10 (10) |
| Indian subcontinent | 36 (38) |
| Africa | 15 (16) |
| Eastern Europe and Russia | 22 (24) |
| No. (%) of patients with the following type of TB (n = 93): | |
| MDR-TB | 73 (78) |
| MDR-TB + FLQr | 12 (13) |
| XDR-TB | 8 (9) |
| No. (%) of patients with the following location of TB (n = 93): | |
| Pulmonary | 41 (44) |
| Extrapulmonary only | 31 (33) |
| Both pulmonary and extrapulmonary | 21 (23) |
| No. (%) of patients receiving the following injectable agent (n = 93): | |
| Capreomycin | 31 (33) |
| Amikacin | 43 (46) |
| Amikacin and capreomycin (sequentially, either order) | 18 (19) |
| Amikacin followed by streptomycin | 1 (1) |
| Baseline (IQR) creatinine concn (μmol/liter) (n = 87) | 66 (58–75) |
| Median (IQR) creatinine clearance (n = 81) | 116.2 (75.7–179.1) |
| Median (IQR) initial dose of injectable agent (mg/kg) (n = 82) | 14.81 (14.06–16.13) |
| Median (IQR) no. of amikacin trough tests/wk (those on amikacin) (n = 58) | 1.01 (0.76–1.29) |
a
Data are for 93 patients. IQR, interquartile range; FLQr, fluoroquinolone resistance.